Surgery First or Chemotherapy First in Ovarian Cancer? How Studies Compare the Options

For advanced ovarian cancer, the first treatment is not always surgery. Starting with chemotherapy can be the recommended approach when a major operation would be too risky or is unlikely to remove all visible cancer.

Surgery first is generally preferred when a patient is fit enough for the operation and a gynecologic oncologist expects to remove all visible disease with acceptable risk.

The decision turns on two questions. Can the cancer be removed completely? Can the patient safely tolerate the surgery needed to do it?

This comparison concerns newly diagnosed stage III or IV epithelial ovarian cancer, including closely related fallopian tube and primary peritoneal cancers. It should not be applied automatically to every ovarian tumor type or to cancer that has returned after treatment.

What Each Treatment Sequence Involves

Both approaches usually combine surgery and chemotherapy. What changes is the order.

Surgery first is called primary debulking surgery or primary cytoreductive surgery. The surgeon removes as much cancer as possible, ideally leaving no visible tumor. Chemotherapy follows recovery.

Chemotherapy first is called neoadjuvant chemotherapy. Treatment begins with medication, followed by reassessment for an operation called interval debulking surgery. Additional chemotherapy usually follows.

The American Cancer Society's ovarian cancer treatment overview describes both sequences for advanced disease. Starting with chemotherapy does not necessarily mean surgery has been ruled out.

It also does not guarantee that surgery will become possible. The team must reassess the cancer's response and the patient's condition.

Why Removing All Visible Cancer Matters

Complete cytoreduction means no cancer remains visible to the surgeon at the end of the operation. You may hear this called complete gross resection or R0.

It does not mean every microscopic cancer cell is gone, and it does not guarantee a cure.

Research consistently associates complete removal of visible disease with better outcomes. That is why the assessment before surgery matters so much. An extensive operation may offer less benefit if substantial disease will remain afterward.

The word “optimal” needs clarification, too. In older ovarian cancer research, optimal debulking often meant leaving tumor deposits no larger than 1 centimeter. That is different from leaving no visible disease. Ask which result your surgeon expects.

How Specialists Decide Which Treatment Comes First

A gynecologic oncologist specializes in cancers of the female reproductive system. This specialist should assess whether an upfront operation is appropriate.

The 2025 ASCO guideline update, endorsed by the Society of Gynecologic Oncology, recommends surgery first for patients who are fit for surgery and have a high likelihood of complete cytoreduction with acceptable complications.

It recommends chemotherapy first when complete cytoreduction is unlikely or the patient's risk from surgery is high.

Where the Cancer Has Spread

The distribution of cancer matters, not just the stage number.

Imaging helps the team assess which organs and tissues are involved and how extensive an operation would need to be. In selected patients, diagnostic laparoscopy allows the surgeon to inspect the abdomen through small incisions.

No scan or scoring system guarantees complete removal. The findings have to be interpreted alongside surgical experience and the patient's health.

Whether the Patient Can Tolerate the Operation

The assessment includes strength, daily functioning, nutrition, frailty, and other medical conditions. Age alone does not answer whether someone can tolerate surgery.

An operation may involve the bowel or other organs in addition to the reproductive organs. The discussion should explain the likely extent of surgery and its risks.

These factors were also central to the earlier joint SGO and ASCO recommendations. They help explain why two people with the same cancer stage may receive different recommendations.

What the Major Trials Found

Randomized trials compare treatment sequences by assigning patients to different groups. Their conclusions apply to the patients and treatment settings studied.

They do not establish that either sequence is best for everyone.

EORTC 55971 and CHORUS Supported Chemotherapy First for Selected Patients

The EORTC 55971 trial studied patients with bulky stage IIIC or IV disease. It found that chemotherapy followed by interval surgery was noninferior to surgery first for overall survival.

“Noninferior” means the study met its prespecified statistical standard for ruling out an unacceptable loss of effectiveness. It does not mean the treatments produced identical results for every patient.

The CHORUS trial also established noninferiority for chemotherapy first in its study population. Serious postoperative complications and deaths shortly after surgery were less frequent in the chemotherapy-first group.

These trials support chemotherapy first as an evidence-based treatment sequence. They do not establish that it should replace upfront surgery for every fit patient with removable disease.

SCORPION Studied Patients With a High Tumor Burden

The SCORPION trial used laparoscopic assessment to select patients with extensive disease.

Chemotherapy first produced fewer major postoperative complications. The study did not find a statistically significant difference in progression-free or overall survival between the sequences.

That finding concerns a selected group with high tumor burden. It should not be treated as a universal rule for all advanced ovarian cancers.

JCOG0602 Did Not Establish Noninferiority

The Japanese JCOG0602 trial did not confirm that chemotherapy first was noninferior to surgery first under its statistical design.

That is an important qualification to the earlier trials. It is also different from proving that surgery first was superior.

A trial can fail to establish noninferiority because the range of plausible results remains too wide. The correct conclusion is that this study did not settle the comparison in favor of chemotherapy first.

TRUST Added Evidence From Centers With Audited Surgical Quality

The TRUST trial results reported at ASCO in 2025 addressed a concern about earlier studies by requiring participating centers to meet surgical quality and volume criteria.

The trial enrolled patients with good functional status and compared upfront surgery with chemotherapy followed by interval surgery.

Surgery first improved progression-free survival, the time before cancer worsened or death occurred. Median progression-free survival was 22.2 months with surgery first and 19.7 months with chemotherapy first.

However, the trial did not demonstrate a statistically significant overall survival advantage for surgery first, its primary endpoint.

Those are different outcomes. A longer period before progression should not be described as proof that patients lived longer overall. The results were reported as a conference abstract, which should also be clear when discussing them.

What New York Informed Consent Law Requires

Under Public Health Law 2805-d, informed consent includes disclosure of reasonable alternatives and reasonably foreseeable risks and benefits that a reasonable practitioner would disclose under similar circumstances.

For this treatment decision, the discussion should address the medically reasonable alternatives for the individual patient. It does not require presenting an unsuitable operation as an equally appropriate choice.

A lack-of-informed-consent claim requires more than showing that an explanation was incomplete. A reasonably prudent person in the patient's position must have declined the treatment if properly informed, and the lack of informed consent must have caused the claimed injury.

A signed form is relevant evidence, but the review also examines what was actually discussed.

Filing Deadlines Depend on the Alleged Error

Under CPLR 214-a, New York medical malpractice claims generally have a two-year-and-six-month filing period, subject to qualifying continuous treatment and other applicable rules.

The statute has a special provision for negligent failure to diagnose cancer. Its discovery-based calculation involves knowledge of both the alleged negligence and the resulting injury, a seven-year limit associated with that provision, and a separate qualifying continuous-treatment alternative.

That provision does not automatically apply to a claim about treatment selection after cancer was diagnosed.

Public-entity requirements and other exceptions can change the process. The alleged error and the responsible provider must be identified before calculating a deadline.

Discuss Concerns About Your Ovarian Cancer Care

If you believe your treatment options were not properly evaluated or explained, preserve the imaging reports, pathology results, consultation notes, consent documents, and treatment timeline.

Porter Law Group can review concerns about an ovarian cancer diagnosis, treatment decision, or delay and explain the legal issues involved.

You can request a review of your ovarian cancer care, call 833-888-LATE, or email info@porterlawteam.com.

This article provides general educational information, not medical or legal advice. Treatment decisions should be made with your cancer care team. Do not postpone recommended medical care while seeking legal advice.

Attorney Advertising. Reading this article or contacting the firm does not create an attorney-client relationship.

Frequently Asked Questions

Is Chemotherapy First a Sign That Ovarian Cancer Cannot Be Treated?

No. Chemotherapy first is an established treatment sequence for selected patients with advanced epithelial ovarian cancer. It may be recommended because immediate surgery carries too much risk or is unlikely to remove all visible disease. The team should explain the treatment goal and whether interval surgery is planned.

Does Stage IV Ovarian Cancer Automatically Rule Out Surgery?

No. Some patients with stage IV ovarian cancer undergo surgery as part of treatment. The recommendation depends on where the cancer has spread, whether meaningful removal is feasible, and whether the patient can tolerate the operation. The stage number alone cannot determine which treatment should come first.

Does Complete Cytoreduction Mean the Cancer Is Cured?

No. Complete cytoreduction means the surgeon has removed all visible cancer. Microscopic disease may remain, which is one reason chemotherapy remains part of treatment. The operative report should distinguish no visible residual disease from a result described as optimal debulking with small tumor deposits remaining.

Should Everyone With Advanced Ovarian Cancer Start With Chemotherapy?

No. Research supports chemotherapy first for selected patients, but it has not established one sequence as best for everyone. Fitness for surgery, disease distribution, and the likelihood of complete removal matter. The newer TRUST results also distinguish an improvement in progression-free survival from a proven overall survival advantage.

Can I Bring a Claim Because My Doctor Recommended Chemotherapy First?

The recommendation alone does not establish a claim. A review must identify an actionable departure from accepted care and resulting harm, or establish the elements of a lack-of-informed-consent claim. Relevant questions include whether your options were appropriately assessed, why the sequence was chosen, and what information you received.